Prompt and reliable detection of drug-resistant tuberculosis (TB) is critical for optimising the treatment regimen and for the success of TB control worldwide. Drug-resistant TB reduces response to standard short-course chemotherapy with first-line anti-TB drugs, leads to higher mortality and treatment failure rates and increases periods of transmissibility of the disease. In view of recent global increase in the incidence of drug-resistant TB, it is prudent to test Mycobacterium tuberculosis (MTB) isolates from all TB patients at least for all first-line TB drugs. Ethambutol (EMB) is a key anti-TB first-line drug which is used in combination with rifampicin (RIF), isoniazid (INH) and pyrazinamide (PZA). Early detection of EMB resistance in TB patients is important as EMB resistance has been associated with multidrug resistance (MDR; defined as resistance to at least RIF and INH) of MTB. [1, 2] Unfortunately, conventional culture-based EMB susceptibility test methods have poor inter-test and inter-laboratory reproducibilities [3, 4] and also time-consuming due to slow growth of MTB. However, the increased understanding of the genetic mechanisms of MTB resistance to EMB leads to the development of various molecular methods (to detect the genetic determinants of EMB resistance) that are potentially more rapid and more accurate than culture-based drug sensitivity tests (DSTs).
The mechanism of resistance to EMB in MTB is associated with mutations in the embCAB gene, encoded by membrane-associated arabinosyl transferases which are organised as operon. [5] [6] [7] Exchanging wild-type embB306, embB497 and embB406 with mutant codons increases the EMB minimal inhibitory concentrations of MTB. [2, 4, 8] Mutations at embB320 and embB324 [8, 9] as well as mutations at embB397, embB445, embB1024 and embC13 have also been found to be associated with EMB resistance. [10] However mutations at 306 th codon in the embB protein play the central role in EMB resistance. [10] [11] [12] Several studies from India have also reported the strong association of embB306 mutations with EMB resistance in MTB isolates. [13] [14] [15] The emb306 mutations have also been proposed as candidate marker for the detection of MDR and extensively drug-resistant MTB isolates. [16, 17] Of the various molecular assays applied for detecting the drug-resistant TB, real-time polymerase chain reaction (PCR) is currently the method of choice with high importance due to its advantage of speed, accuracy and minimum risk of contamination. In the study described here, we developed a real-time PCR hybridisation probe method which can be directly applied on clinical specimen for the early detection of EMB susceptibility in both drug-sensitive and drug-resistant pulmonary TB cases. Two fluorescent probes potential to differentiate between the wild type and mutant alleles of codon 306 in embB gene region were designed and mutations were detected by fluorescence resonance energy transfer (FRET) probe melting curve analysis using real-time PCR platform.
The diagnostic value of indigenous molecular assay in the determination of EMB resistance/susceptibility was assessed by comparing with gold standard 1% proportion method (on Lowenstein-Jenson [L-J] media), whereas, to validate the accuracy of our real-time PCR-based assay in detecting the genetic mutation, gold standard DNA sequencing method is used. Along with evaluating the potential of developed method, the undertaken work shows the distribution frequency of EMB gene mutation and its correlation with predominant nucleotide change and high level of therapeutical relevance of resistance to EMB in MTB clinical isolates.
matErials anD mEtHODs

Collection of sputum and isolation of Mycobacterium tuberculosis strains and their susceptibility testing
A total of 52 MTB cultures and also their sputum samples (mentioned sputum and culture samples here onwards) obtained from Category II pulmonary TB cases belonging to Agra region were included in the study. These cases were referred to the Department of Microbiology and Molecular Biology, National JALMA Institute for Leprosy and Other Mycobacterial Diseases (NJIL&OMD), Agra, and the samples were collected (during 2007-2008) as per prior approval of Institutional Ethical Committee of NJIL&OMD, Agra. On the basis of Revised National Tuberculosis Control Program guidelines, clinical sputum samples of pulmonary TB cases were subjected to smear microscopy for the confirmation of acid-fast bacilli and were cultured on L-J media and were incubated at 37°C. Biochemical identification of MTB colonies was done on the basis of niacin production. [18] The drug susceptibility testing was done by proportion method (with critical concentration of 2 µg/ml for EMB) on L-J medium. [19] Reference MTB strain H 37 Rv was included as sensitive control in drug susceptibility testing. All the inoculated samples were incubated at 37°C for 6 weeks till the final readings. An isolate was considered resistant if it had a growth of >1% on drug-containing medium in comparison to the drug-free medium. [19] 
Isolation of genomic DNA from clinical specimen and Mycobacterium tuberculosis culture isolates
Genomic DNA from each MTB culture isolate was extracted using the cetyl trimethyl ammonium bromide method as described by van Soolingen et al. [20] Whereas, DNA from sputum MTB bacilli was extracted (soon after collection) using the method adapted from Boom et al. [21] All respiratory specimens had been decontaminated previously by the N-acetyl-L-cysteine-NaOH conventional method. [22] The extracted DNA from sputum samples was stored at −80°C till further analysis by real-time PCR (after the culture, biochemical and drug susceptible testing results became available).
Designing of primers and probes
Two primers and two hybridisation probes for the region spanning 306 codon of MTB were designed by using the nucleotide sequence of embB from MTB genome database server (Tuberculist: http://genolist.pasteur.fr/TubercuList/). The nucleotide sequence of primers and probes is summarised in Table 1 that yielded amplicon of 175 bp. The sensor probe was labelled with a Light Cycler Red 640 fluorophore (TibBiol, Germany) at the 5' and phosphorylated at 3 end so that it cannot be extended. The Anchor probe was labelled with fluorescein at the 3' (TibBiol, Germany). The sequences of the two probes are selected so that they can hybridise to the target sequences in a head-to-tail arrangement, bringing the two dyes very close to each other, allowing FRET.
Hybridisation probe (fluorescence resonance energy transfer)-based real-time polymerase chain reaction assay
DNA isolated directly from clinical sputum samples and culture isolates from them, the standard strain of MTB (H 37 Rv), were used as positive control. The real-time PCR mixture was prepared in a final volume of 20 µl, including 2 µl ready-to-use reaction mix (Roche Diagnostics, GmbH, Germany) which contained Taq DNA polymerase, reaction buffer, dNTP mix and 10 mM MgCl 2. Further, a final concentration of 4 mM of MgCl 2 , 0.5 and 0.2 µM concentration of each primers and probes, respectively, and 10 ng of template DNA were added in reaction mixture. The reaction was performed in a closed glass capillary after proper mixing and brief centrifugation. The cycling conditions were 95°C for 5 min followed by 45 cycles of 95°C for 10 s, 56°C for 15 s and 72°C for 20 s with continuous monitoring of fluorescence during the annealing phase, followed by a melting programme of 45°C-90°C at 0.1°C/s with continuous fluorescence monitoring in real-time detection system (Roche Diagnostics, GmbH, Germany). [23] A negative control without a DNA sample and a standard wild-type control with DNA of H 37 Rv were included for every real-time PCR experiment. The melting curve was analysed using Light Cycler software 2.0 version (Roche Diagnostics, GmbH, Germany).
DNA sequencing and sequence analysis
The sequencing of amplicon was carried out using the ABI PRISM 310 (Applied Biosystems, Foster City, CA, USA) automated DNA sequencer as per manufacturer's instructions. Sequences generated by DNA sequencer were compared with wild-type sequences of H 37 Rv strain of MTB using ClustalW tool (www.ebi.ac.ul/services/clustalw). [24] Identified mutations were then translated to detect amino acid changes at specific locations using Translate (www.ebi. ac.ul/translate). [19, 25] Sensitivity and specificity of EMB were calculated on the basis of susceptibility pattern found by gold standard phenotypic proportion method. The result of indigenous real-time PCR assay (to detect the mutations at emb306 region) was validated by gold standard sequencing method for nine randomly selected EMB-resistant MTB isolates. The concordance of hybridisation-based real-time PCR was calculated with the two gold standard methods, i.e., phenotypic proportion method and genotypic DNA sequencing method.
rEsults
Among 52 biochemically characterised MTB isolates, twenty were found susceptible to EMB, while the remaining 32 MTB isolates showed resistance to EMB by standard L-J proportion method [ Table 2 ]. The real-time PCR experiment revealed melting temperature (T m ) of emb306 probes as 54.64°C for wild-type control strain H 37 Rv. Whereas, mismatch at mutant codon emb306 (GTG → ATG) resulted in a >10°C decrease in the T m of probes [ Figure 1 ]. Overall, EMB-resistant MTB strains showed clear variation in T m from that of wild-type control strain H 37 Rv. Out of 32 EMB-resistant MTB cultures [as determined by L-J proportion method showed in Table 3 ] as well as the corresponding clinical (sputum) samples, we were able to detect mutation in 24 EMB-resistant MTB culture samples and their sputum samples by our in-house designed specific primers and probes encoded for 306 codon of embB gene region of EMB. Rest of the eight EMB-resistant isolates did not show mutation at this codon. In case of twenty EMB-sensitive MTB cultures as well as their clinical (sputum) samples of the same culture type, 19 MTB samples showed wild-type sequence as their T m was in accordance to that of wild-type control strain H 37 Rv (T m 54.64°C). However, the remaining one EMB-sensitive culture and also clinical (sputum) of the same culture type showed mutation at 306 codon of embB gene region of EMB on the basis of >10°C variation in melting T m from that of wild-type control strain H 37 Rv.
With respect to sensitivity and specificity of our hybridisation probe-based real-time PCR method, 75% sensitivity and 95% specificity were observed for the detection of EMB resistant/susceptible MTB, both in culture and their sputum samples, with a 100% concordance in both the types of samples [ Table 3 ]. The EMB susceptibility testing by real-time PCR hybridisation probe method showed 82.69% concordance when compared with standard L-J proportion method.
DNA sequencing of nine randomly selected EMB-resistant MTB isolates did not show any mutation in three pan-susceptible isolates. Whereas, the remaining six EMB-resistant MTB isolates (which showed mutation at codon 306 by real-time PCR) showed change in amino acid Met306Val (ATG-GTG) in embB gene of EMB. Therefore, concordant results were found by DNA sequencing Table 4 ].
DiscussiOn
Rapid diagnosis and timely initiation of treatment is crucial for the management of drug-resistant TB in any TB control programme. DST by conventional phenotypic method requires much more time, thus resulting into unacceptable delay in diagnosis. Owing to the potential and reliability of DNA-based test, the WHO endorsed line probe assay and Xpert MTB/RIF for early diagnosis of MDR-TB. These tests though may appear costly are not actually if we consider benefits gained by timely treatment and reduced transmission from secondary cases. As a commendable step, India is gradually moving towards decentralised deployment of DNA-based rapid DST facility up to district level throughout the country. However, these tests do not predict the resistance to EMB which continues to be used as part of a standard anti-tubercular drug regimen. Moreover, the emergence of EMB resistance with INH resistance in large percentage [26] and association of EMB resistance with MDR necessitate the rapid detection of EMB resistance. [16] The present study was designed to provide a rapid detection of EMB-resistant mutation of MTB directly from clinical specimen (sputum) using two FRET probes targeting embB306 locus. Methods based on FRET hybridisation probes [23, 27] have been reported more useful for detecting the drug susceptibility using real-time PCR and have several advantages such as rapid amplification and analysis. Hybridisation probes have been successfully applied earlier for the detection of INH-and RIF-resistant MTB isolates. [23] However, its potential to detect EMB-resistant MTB has never been investigated. In this study, wild-type control strain H 37 Rv showed 54.64°C T m of probes, whereas the EMB-resistant mutant strains showed T m >10°C as compared to the wild-type control. Similarly, Luo et al. [28] also detected high deviation (>10°C) in few MTB isolates with mutations in embB306 as compared to T m of H 37 Rv. In the present study, EMB-sensitive strains showed T m in accordance to that of susceptible wild-type control strain H 37 Rv (T m 54.64°C). We found 75% mutations at 306 codon which was confirmed by randomly selected EMB-resistant strains which showed >10°C variation in T m from that of wild-type control strain H 37 Rv by real-time PCR (targeting 306 codon of embB gene by in-house designed primers and probes). Therefore high deviation in T m of probes between mutant-and wild-type isolates/sputa (which can be detected by almost all real-time PCR platforms by melting analysis) indicates the promise of this newly developed method.
Although EMB resistance is a complex issue and multilocus mutations are suggested to be associated, [2, 8, 9] many studies showed that about 65% clinical isolates harbour mutation at 306 amino acid position, forming EMB resistance-determining region. Since mutations may vary by geographic area, it will be interesting to identify mutation that is strongly associated with resistance. Few previous studies from India reported that 59%-69% of EMB-resistant MTB isolates had polymorphism in embB gene. [13, 14] Our study is also in agreement, as emb306 mutation was detected in majority (75%) of EMB-resistant isolates and sputa. However, we could not detect 25% of EMB-resistant strains, may be due to other mechanisms of EMB resistance or mutation at other locus. [2, 8, 9] Therefore, lack of a mutation in the target sequence must be interpreted with caution.
Our real-time PCR method was found to be 95% specific for the detection of EMB-susceptible isolates/sputa. Since the phenotypic susceptibility testing was repeated for one EMB-susceptible isolate (1/20) that could not be detected by our real-time PCR, we reasoned for the lack of 5% specificity of assay, possibly due to the mixed bacterial population (heteroresistance). [29] According to the previous Indian studies, [13] [14] [15] embB 306 amino acid position is highly associated with EMB resistance in MTB isolates, these studies support our findings which suggest that the embB306 mutations can be used as useful markers for direct detection of EMB-resistant MTB clinical isolates in India. These previous findings also provide the molecular evidence of EMB-resistant clinical isolates, which supports our study in direct use of MTB sputum samples for rapid detection of EMB-resistant mutation.
Interestingly, there was 100% concordance in the result profile of both specimen types (sputum samples as well as their MTB cultures), which supports the reliability of clinical sputum samples for rapid detection of EMB susceptibility testing. On the basis of 100% concordance observed, there is good evidence for supporting further studies of rapid detection by using sputa of pulmonary TB cases. Moreover, real-time PCR result showed 100% concordance also with sequencing method. On the basis of sequencing results, we found that amino acid change of ATG-GTG (Met306Val) was most prominent in our findings, which indicates that it could be the most common genetic determinant responsible for EMB resistance in Indian MTB isolates. [13] [14] [15] A limitation particular to the current study is that we targeted only one codon (emb306) for detecting the EMB resistance which resulted into moderate sensitivity of developed method. However, sensitivity of the method may be enhanced up to acceptable level by further optimisation and evaluation of this method to target other potential genetic determinant sites (embB306, embB497, embB406, etc.) too.
cOnclusiOn
We have developed a new real-time PCR method for the rapid detection of EMB drug-resistant mutations in MTB isolates as well as directly from clinical specimens. The developed method has utility to be used as a supplementary test with the direct use of MTB sputum samples for rapid detection of drug-resistant mutations. Our results demonstrate 75% of EMB resistance conferred by mutation at embB306 codon; this percentage and sensitivity of method can be increased by targeting additional important loci in future studies.
